Key facts
- Epicrispr Biotechnologies’s last known valuation is $185.0M (Jul 2022).
- It has raised $123.0M; the latest was Later Stage VC ($68.0M) in Mar 2025.
- Notable investors include Horizons Ventures, LDV Partners, Ally Bridge Group, Solve FSHD.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Epicrispr Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Epicrispr Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epicrispr Biotechnologies
Developer of gene therapies designed to treat various genetic diseases that currently lack effective treatments. The company focuses on precisely regulating gene activity by turning genes on or off through epigenetic modifications, enabling healthcare professionals to reduce symptoms, prevent disease progression, and improve the quality of life for people with serious genetic disorders
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 43
- Website
- epicrispr.com/
- Ownership
- Privately Held (backing)
Epicrispr Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epicrispr Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epicrispr Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.